Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of TRPA1 inhibitor in preparation of medicine for treating multiple sclerosis

A multiple sclerosis, inhibitor technology, applied in the application of multiple sclerosis drugs, the field of TRPA1 inhibitors, can solve problems such as cell damage and cell membrane rupture

Inactive Publication Date: 2020-08-04
广州浚远康生物科技有限公司
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are two main hypotheses, one is that LPC can cause cell membrane rupture, thereby causing cell damage; the other is that LPC acts on receptors on the cell membrane, causing downstream signals such as oxidative stress and inflammatory responses, and ultimately causing cell damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TRPA1 inhibitor in preparation of medicine for treating multiple sclerosis
  • Application of TRPA1 inhibitor in preparation of medicine for treating multiple sclerosis
  • Application of TRPA1 inhibitor in preparation of medicine for treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: TRPA1 regulates the oxidative stress and cell damage of OLN-93 oligodendrocytes caused by LPC

[0020] 1. Material

[0021] 1.1 The main instruments and reagents

[0022]

[0023]

[0024]

[0025]

[0026] 1.2 Main cell sources

[0027] Rat oligodendrocyte cell line OLN-93, purchased from Cybertron (Shanghai) Biotechnology Co., Ltd., catalog number iCell-r023.

[0028] 2. Method

[0029] 2.1 Cultivation of OLN-93 oligodendrocytes

[0030] The OLN-93 oligodendrocytes were cultured in DMEM complete medium containing 10wt% fetal bovine serum at 37℃, 5% CO 2 .

[0031] 2.2 Immunofluorescence detection of TRPA1 and nNOS in OLN-93 oligodendrocytes

[0032] (1) Cultivating OLN-93 oligodendrocytes in 4 cells of 3.5cm glass-bottom dishes, the amount of cells in each cell is 1×10 5 Each, cultured overnight in a cell incubator.

[0033] (2) Rinse with PBS 3 times, fix the cells with 4wt% paraformaldehyde at room temperature for 15 minutes.

[0034] (3) Rinse with PBS 3 times, 3 minute...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a TRPA1 inhibitor in preparation of a medicine for treating multiple sclerosis. The TRPA1 inhibitor can be used for preparing a medicine for treating multiplesclerosis caused by lysophosphatidylcholine (LPC). According to the application, by establishing an OLN-93 oligodendrocyte oxidative stress and cytotoxicity model, the expression of TRPA1 on OLN-93 oligodendrocytes and oxidative stress and cell damage caused by participation of TRPA1 in LPC induction are explored. Research results show that the TRPA1 inhibitor can significantly inhibit calcium ion internal flow in cytoplasm and mitochondria, significantly reduce mitochondrial active oxygen production, significantly inhibit mitochondrial membrane potential reduction, significantly inhibit NO production, significantly inhibit superoxide increase and effectively inhibit oligodendrocyte toxicity increase. Therefore, it is possible to treat demyelinating diseases such as multiple sclerosis caused by LPC using an inhibitor of TRPA1.

Description

Technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to the application of TRPA1 inhibitors in the preparation of drugs for the treatment of multiple sclerosis, and in particular to the application of TRPA1 inhibitors in the preparation of drugs for the treatment of multiple sclerosis caused by lysophosphatidylcholine . Background technique [0002] Lysophosphatidylcholine (LPC) is an important phospholipid molecule in the human body, which is catalyzed by phospholipase A2. LPC is often used to construct demyelinating animal models in experiments. LPC can cause inflammation of astrocytes and microglia and cause oligodendrocyte damage. In the cerebrospinal fluid of patients with demyelinating diseases such as multiple sclerosis, the content of LPC is significantly increased. As an important demyelinating medium, the specific mechanism of LPC is still unclear. There are two main hypotheses. One is that LPC can cause cell membrane r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/15A61K31/522A61P25/00A61P37/02
CPCA61K45/06A61K31/15A61K31/522A61P25/00A61P37/02
Inventor 李志远田超徐浚杰汤凤刘雨杰
Owner 广州浚远康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com